Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2326 to 2340 of 7681 results

  1. Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and living with overweight or obesity ID6441

    In development [GID-TA11544] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor TS ID 8376

    Awaiting development [GID-TA11608] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Seladelpar for previously treated primary biliary cirrhosis ID 6429

    Awaiting development [GID-TA11609] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis TS ID 12050

      Status ...

    Technology appraisal guidance
    Topic selection

  5. Sotatercept for treating pulmonary arterial hypertension [ID6163]

    In development [GID-TA11103] Expected publication date: 15 October 2025

    Technology appraisal guidance
    In development

  6. Cabozantinib for treating advanced pancreatic or extra-pancreatic neuroendocrine tumours that have progressed after systemic treatment TSID 12078

    Awaiting development [GID-TA11613] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Budesonide oral suspension for maintaining remission of eosinophilic oesophagitis in people 2 years and over TS ID 12082

      Status ...

    Technology appraisal guidance
    Topic selection

  8. Relugolix–estradiol–norethisterone for treating symptoms of endometriosis [ID3982]

    In development [GID-TA10873] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]

    Awaiting development [GID-TA11470] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]

    Awaiting development [GID-TA11440] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Acne

    Awaiting development [GID-QS10036] Expected publication date: TBC

    Quality standard
    Awaiting development

  12. Primary hyperparathyroidism

    Awaiting development [GID-QS10089] Expected publication date: TBC

    Quality standard
    Awaiting development

  13. School-based interventions: physical and mental health and wellbeing promotion

    In development [GID-QS10070] Expected publication date: TBC

    Quality standard
    In development

  14. Linzagolix for treating symptoms of endometriosis [ID6357]

    In development [GID-TA11376] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  15. Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897

    In development [GID-TA11437] Expected publication date: TBC

    Technology appraisal guidance
    In development